Scripta Insights Launches GLP-1 Navigator As Americans Scramble For Weight Loss Drug Answers

(MENAFN- PR Newswire) This comes at a pivotal time when GLP-1 medications like Ozempic, Wegovy and Zepbound have surged in popularity transforming obesity and diabetes care with an estimated 30 million Americans in the market for weight loss treatments . With prices fluctuating wildly, coverage rules shifting daily, and a flood of new vendors entering the market, navigating GLP-1s has become a full-time job for patients.

Updated weekly, Scripta's GLP-1 Navigator helps members understand their options and the trade-offs-regardless of whether their plan covers GLP-1s-including guidance around:

• Brand/formulation differences
• Delivery methods and side effects
• Cash pay vs. insurance options
• How to compare vendors, suppliers and prices

"GLP-1s have the potential to be life changing for millions of Americans-but the GLP-1 market is like the Wild West. Both doctors and patients struggle to understand the best option for getting these important treatments in an affordable, and sustainable way," said Eric Levin, CEO of Scripta Insights. "If information is changing in as little as a day, how can we expect everyday Americans, doctors, or even HR and benefits leaders, to make sense of it all? At Scripta, we're here to break down those barriers and help plan members understand their options while reducing the confusion, stress and the guesswork that is standing in the way of better health."

The GLP-1 Navigator is part of Scripta's larger Rx Navigation platform, a tailored solution for plan sponsors to better manage skyrocketing pharmacy benefit costs, while helping their members get The Right Meds at The Best PriceTM. As with other prescription drugs, the Scripta app also navigates members to more affordable GLP-1 proven alternatives based on their plan design and formulary.

Scripta will host a timely expert-led webinar , "GLP-1s Right Now: Navigating Access, Affordability & Outcomes for Self-Insured Plan Sponsors ," for HR and benefits professionals on Wednesday, May 21^st at 1 P.M. ET addressing the latest breaking GLP-1 news and clinical developments impacting their members:

• CVS Caremark's decision to drop coverage of Zepbound
• WeightWatchers filing for bankruptcy
• Looming federal deadlines to stop compounding
• Direct-from-manufacturer GLP-1 availability

The webinar's panel of clinical, pharmacy benefit and consumer experts, including Dr. Paul Bradley, Scripta's Chief Medical Officer, a practicing internist and nationally recognized obesity and clinical research expert, will help translate the chaos with practical strategies plan sponsors can implement now, while preparing for what's next. Plus, coverage considerations and a first look at Scripta's GLP-1 Navigator. This event is free to attend for HR and benefits professionals and accredited media, but registration is required. Attendees can register online here .

About Scripta Insights

Scripta Insights, a venture-backed digital health company, is a leader in developing pharmacy navigation solutions for self-insured employers, health plans and their members. The company was founded in 2019, following nearly a decade of work by doctors, pharmacists and data analysts who helped build Scripta's proprietary software platform. For more information about Scripta, visit and follow the company on LinkedIn .

CONTACT : Elizabeth Tran, LKPR, Inc. for Scripta Insights, [email protected] , 973-885-0056

SOURCE Scripta Insights

MENAFN20052025003732001241ID1109571552